In the SUSTAIN 7 randomized controlled trial, once-weekly subcutaneous semaglutide (OW) (s.c.) 0.5mg was associated with greater reduction in glycated hemoglobin (HbA1c) and body weight people type 2 diabetes mellitus (T2DM) comparing dulaglutide 1.5mg. The present study estimated annual cost per patient achieving HbA1c treatment targets loss responses OW s.c. Chinese healthcare system setting ...

Liraglutide, a glucagon-like peptide (GLP-1) receptor agonist, has showed favorable effects in the glycaemic control and weight reduction in patients with type 2 diabetes mellitus (T2DM). The meta-analysis was to compare the efficacy and safety of liraglutide added to metformin with other treatments in patients with T2DM. A systematic literature search on PubMed, Embase, Web of Science and the ...